

Date: 14/11/2022

To Dept. of Corporate Services, BSE Limited, Floor 25, P J Tower, Dalal Street, Mumbai - 400001.

Scrip code: 526445

Dear Sir/Madam,

Sub: Outcome of the Board Meeting.

Ref: Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please refer our letter dated November 05, 2022 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In continuation, we wish to inform that at the meeting of Board of Directors held today i.e., on **November 14, 2022**, the Directors have *inter-alia* considered and approved the following amongst other subject matters:

- Unaudited Financial Results (Standalone and Consolidated) with the Limited Review Report of the Company for the quarter and half year ended September 30, 2022 (Q2), pursuant to Regulation 33 of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Investment of Rs.30,00,000 (Thirty Lakhs only) in the equity shares of Matrix Boilers Private Limited in order to acquire it as Subsidiary of our company.
- Loan of Rs.10,00,00,000 (Ten Crores only) to meet working capital requirement and other financial commitments of Matrix Biolers Private Limited.

We, herewith, have attached the copy of the unaudited financial results (standalone and consolidated) for the quarter ended September 30, 2022 along with the Limited Review Report for the said period.

The Board Meeting commenced at 6:45 p.m. and concluded at 7:20 p.m. The necessary arrangements are in place to publish the unaudited financial results in the newspapers. The said financial results will also be available on company's website www.indrayani.com and also on BSE website www.bseindia.com.

We request you to kindly take the same on your records.

Thanking you.

Yours faithfully,

For Indrayani Biotech Limited

Kasiraman Sayee Sundar Managing Director

DIN: 01295584



VENKATESH & CO

Chartered Accountants

Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015

To The Board of Directors Indrayani Biotech Limited

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **30**th **September, 2022** and for the period from **1**st **July 2022 to 30**th **September 2022** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI x(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended **30**th **September, 2021** and corresponding period from 1st July 2021 to 30th September 2021 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the unaudited results of the following entities:

- i. HSL Agri Solutions Limited Subsidiary
- ii. IBL Healthcare Limited Subsidiary
- Dindigul Farm Product Private Limited Subsidiary
- iv. IBL Thiruvannamalai LLP Step down Subsidiary

v. HSL Prime Properties Private Limited - Subsidiary

SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai 600 017.

Telefax: 2814 4763/64/65/66 Email: venkateshandco@gmail.com

Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the financial statement / financial information of **4 Subsidiaries** included in the consolidated unaudited financial results, whose interim financial information for the Period ended 30th September, 2022 reflects total revenues of ₹ **5,013.08 Lakhs**, total comprehensive profit / (loss) of ₹ **454.76 Lakhs** for the period ended on that date in respect of **M/s. IBL Thiruvannamalai LLP** (stepdown subsidiary) included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of ₹ **9.63 Lakhs**, total net profit / (Loss) after tax of ₹ **(4.06) Lakhs** for the period ended on that date, as considered in the consolidated financial results.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

for Venkatesh & Co

Chartered Accountants

FRN: 004526S

A Dasaraty V

Partner

M No: 026336

UDIN: 22026336BDBSVG2301

Chennai, 14th November 2022

INDRAYANI BIOTECH LIMITED

Regd. Office:

BLOCK 1, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2022

1 Income from (a) Net Sales (b) Other Inc. Total Income 2 Expenses (a) Cost of M (b) Changes goods, work-i (c) Employee (d) Finance C (e) Depreciat expense (f) Other expense (f) Other expense (f) Other expense (f) Total profit / items and ta: 4 Exceptional I Add:Share of Total profit / 7 Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Los continuing o Profit (loss) operations b Tax expense 10 operations b Tax expense 10 operations b Tax expense 11 operation aft Share of pro joint venture equity metho 12 equity metho 13 Total profit (Other compense taxes Total Compense period attribut noncontrolling 16 Details of ec Paid-up equ Face value of							Rs. In Lakhs
1 Income from (a) Net Sales (b) Other Income Total Income 2 Expenses (a) Cost of M (b) Changes goods, work-i (c) Employee (d) Finance C (e) Depreciat expense (f) Other expense (f) Other expense (f) Other expense (f) Other expense (f) Total profit / items and ta: 4 Exceptional I Add:Share of Total profit / 7 Tax Expense Current Tax Deferred Tax Deferred Tax Total Tax Ex Net Profit Lo continuing o Profit (loss) operations b Tax expense operations Net profit (loss) operations Net profit (loss) for operation aft Share of pro joint venture equity metho 11 Other compense attributable to Total compre period attribut noncontrolling Details of ec Paid-up equ Face value of		CONSOLIDATED					
1 Income from (a) Net Sales (b) Other Income Total Income 2 Expenses (a) Cost of M (b) Changes goods, work-i (c) Employee (d) Finance C (e) Depreciat expense (f) Other expense (f) Other expense (f) Other expense (f) Other expense (f) Total profit / items and ta: 4 Exceptional I Add:Share of Total profit / 7 Tax Expense Current Tax Deferred Tax Deferred Tax Total Tax Ex Net Profit Lo continuing o Profit (loss) operations b Tax expense operations Net profit (loss) operations Net profit (loss) for operation aft Share of pro joint venture equity metho 11 Other compense attributable to Total compre period attribut noncontrolling Details of ec Paid-up equ Face value of			Quarter Ended		Half Yea	r Ended	Year Ended
(a) Net Sales (b) Other Inc. Total Income 2 Expenses (a) Cost of M (b) Changes goods, work-i (c) Employee (d) Finance C (e) Depreciat expense (f) Other profit // (f) Total profit // (f) Total profit // (f) Total profit // (f) Total Tax Expense (f) Other for income (f) (f) Operations b (f) Tax expense (f) Other compense (f) Othe	PARTICULARS	30-09-2022	30-06-2022	30-09-2021	30-09-2022	30-09-2021	31-03-2022
(a) Net Sales (b) Other Inc. Total Income 2 Expenses (a) Cost of M (b) Changes goods, work-i (c) Employee (d) Finance C (e) Depreciat expense (f) Other profit // (f) Total profit // (f) Total profit // (f) Total profit // (f) Total Tax Expense (f) Other for income (f) (f) Operations b (f) Tax expense (f) Other compense (f) Othe		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(a) Net Sales (b) Other Inc. Total Income 2 Expenses (a) Cost of M (b) Changes goods, work-i (c) Employee (d) Finance O (e) Depreciat expense (f) Other expense (f) Other expense (f) Other expense 1 Exceptional I Add:Share of Total profit / Total Tax Expense Current Tax Deferred Tax Deferred Tax Total Tax Ex Net Profit (loss) poperations b Tax expense continuing of Profit (loss) poperation aft Share of proficit of Coperation aft Share of proficit of Total profit (loss) Tax expense Tax expense Total Compense To	from Operations						
(b) Other Inc. Total Income 2 Expenses (a) Cost of M (b) Changes goods, work-i (c) Employee (d) Finance Other (e) Depreciate expense (f) Other Inc. (g) Total profit / (h) Total profit / (h) Total Tax Expense (h) Other Compense (h) Oth	Sales/Revenue from Operations	4,205.30	2,563.21	1,485.24	6,768.51	2,916.46	6,157.18
2 Expenses (a) Cost of M (b) Changes goods, work-i (c) Employee (d) Finance C (e) Depreciat expense (f) Other lexpense (er Income	196.41	39.39	3.70	235.80	6.26	22.08
(a) Cost of M (b) Changes goods, work-i (c) Employee (d) Finance C (e) Depreciat expense (f) Other expense (f) Other expense (f) Other expense (f) Total Expense Total profit / Exceptional I Add:Share of Total profit / Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo continuing o Profit (loss) operations b Tax expense 10 operations b Tax expense 10 operations b Tax expense 11 operation aft Share of profictions Net profit (loss) Other compense 12 equity method 13 Total profit (loss) Other compense 14 taxes Total Compense 15 Comprehens attributable to Total comprehens	come from Operations	4,401.70	2,602.61	1,488.94	7,004.31	2,922.72	6,179.26
(a) Cost of M (b) Changes goods, work-i (c) Employee (d) Finance C (e) Depreciat expense (f) Other expense (f) Other expense (f) Other expense (f) Total Expense Total profit / Exceptional I Add:Share of Total profit / Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo continuing o Profit (loss) operations b Tax expense 10 operations b Tax expense 10 operations b Tax expense 11 operation aft Share of profictions Net profit (loss) Other compense 12 equity method 13 Total profit (loss) Other compense 14 taxes Total Compense 15 Comprehens attributable to Total comprehens	200						
(b) Changes goods, work-i (c) Employee (d) Finance C (e) Depreciat expense (f) Other expense (f) Othe	t of Materials consumed	3,022.79	1,615.76	969.90	4,638.55	1,910.58	4,104.29
goods, work-i (c) Employee (d) Finance (e) Depreciat expense (f) Other expense (f) Other expense Total Expen Total profit / items and ta: 4 Exceptional I Add:Share of Total profit / Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo continuing o Profit (loss) perations b Tax expense continuing o Profit (loss) perations b Tax expense to operations Net profit (loss) peration aft Share of pro joint venture equity metho Total profit (loss) Other compilation Total compre period attribut Total compre period attribut noncontrolling Details of ec Paid-up equ Face value of	nges in inventories of finished	(281.94)	1,013.70	303.30	4,000.00	1,010.00	4,104.20
(c) Employee (d) Finance (e) Depreciate expense (f) Other for the fit of							
(d) Finance (e) Depreciate expense (f) Other exp	vork-in-progress and stock-in-trade	-			(281.94)		
(d) Finance (e) Depreciate expense (f) Other exp	lavaa hanafita ayaanaa	E04 01	120.61	279.24	943.45	573.95	1,021.64
(e) Depreciate expense (f) Other expense (f) Oth	ployee benefits expenses	504.81	438.64				
expense (f) Other expense Total profit / items and ta: Exceptional Add:Share of Total profit / Total profit / Total profit / Total profit / Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo continuing of Profit (loss) perations by Tax expense operations Net profit (lo 11 operation aft Share of proficit yenture equity method Total profit (lo Other competence Total Competence taxes Total Competence taxes Total Competence attributable to Total compreperiod attribut Total compreperiod attribut noncontrolling Details of ec Paid-up equ Face value of		115.16	96.95	52.90	212.11	85.14	187.97
(f) Other expended Total Expended Total profit / items and ta: 4 Exceptional Add:Share of Total profit / Total profit / Tax Expense Current Tax Deferred Tax Deferred Tax Total Tax Expense Current Tax Deferred Tax Profit (loss) operations be Tax expense operations Net profit (loss) operations Net profit (loss) operation after Share of proficion operation after Share of proficion of taxes Total Compete period attributed to Total compreperiod attributed to Total compreperiod attributed Total Compreperiod Attrib	reciation and amortisation	74.96	66.41	40.70	444.07	04.00	05.04
Total Expen Total profit / items and ta: Exceptional I Add:Share of Total profit / Total profit / Total profit / Tax Expense Current Tax Deferred Tax Deferred Tax Total Tax Ex Net Profit Lo continuing o Profit (loss) operations b Tax expense operations Net profit (lo 11 operation aft Share of pro joint venture equity method Total profit (Other compitaxes Total Compitaxes Total Compitate Total compitate Comprehens attributable to Total compre period attribut noncontrolling Details of ec Paid-up equ Face value of				10.72	141.37	21.38	65.94
Total profit / items and ta: Exceptional I Add:Share of Total profit / Total profit / Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo continuing o Profit (loss) operations b Tax expense operations Net profit (lo 11 operation aft Share of pro joint venture equity method Total profit (lo 13 Total profit (lo 14 Other competance) Total Competance Total Competance Total Competance taxes Total Competance Total competance Total compreperiod attribut Total compreperiod attribut Total compreperiod attribut noncontrolling Details of ec Paid-up equ Face value of	r expenses	415.20	206.11	72.02	621.31	164.21	354.23
3 items and ta: 4 Exceptional I Add:Share of 5 Total profit / 6 Total profit / 7 Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo continuing o Profit (loss) operations b Tax expense 10 operations Net profit (lo 11 operation aft Share of pro joint venture 12 equity metho 13 Total profit (Other composit 14 taxes Total Composit 15 Comprehens attributable to Total compre period attribut noncontrolling 16 Details of ec Paid-up equ Face value of	xpenses	3,850.99	2,423.86	1,384.78	6,274.85	2,755.26	5,734.07
4 Exceptional I Add:Share of Total profit // Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo continuing of Profit (loss) operations Net profit (loss) operations Net profit (loss) operations Net profit (loss) operation aft Share of profic (loss) operation aft Share of profict (loss) Other competions 13 Total profit (loss) Other competions attributable to Total compreperiod attribut noncontrolling 16 Details of ec Paid-up equ Face value of	rofit / (Loss) before exceptional						16821 3
4 Exceptional I Add:Share of Total profit // Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo continuing of Profit (loss) operations Net profit (loss) operations Net profit (loss) operations Net profit (loss) operation aft Share of profic (loss) operation aft Share of profict (loss) Other competions 13 Total profit (loss) Other competions attributable to Total compreperiod attribut noncontrolling 16 Details of ec Paid-up equ Face value of		550.71	178.75	104.16	729.46	167.46	445.19
Add:Share of Total profit / 6 Total profit / 7 Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Los continuing of Profit (loss) operations by Tax expense Operations Net profit (loss) operations Net profit (loss) operation aft Share of profic (loss) operation aft Share of proficion for the compression of taxes Total profit (loss) Other compression attributable to Total compression attributable to Tot				-		1.06	
5 Total profit // 6 Total profit // 7 Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo continuing of Profit (loss) operations Net profit (lo 11 operation aft Share of proficion for the compense 12 equity method 13 Total profit (lo 14 taxes Total Compense 15 period attribut Comprehens attributable to Total compre period attribut noncontrolling 16 Details of ec Paid-up equ Face value of	are of Profit In Associates	(25.00)		(0.14)	(25.00)		
6 Total profit / 7 Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo 8 continuing o Profit (loss) 9 operations b Tax expense 10 operations Net profit (lo 11 operation aft Share of pro joint venture 12 equity metho 13 Total profit (Other composity Comprehens attributable to Total compre period attribut noncontrolling 16 Details of ec Paid-up equ Face value of	rofit / (Loss) before tax	525.71	178.75	104.02	704.46	168.52	445.19
7 Tax Expense Current Tax Deferred Tax Total Tax Ex Net Profit Lo 8 continuing o Profit (loss) 9 operations b Tax expense 10 operations Net profit (lo 11 operation aft Share of pro joint venture 12 equity metho 13 Total profit (Other compitates Total Compitates Comprehens attributable to Total compre period attribut noncontrolling 16 Details of ec Paid-up equ Face value of	rofit / (Loss) before tax						
Current Tax Deferred Tax Total Tax Ex Net Profit Lo continuing o Profit (loss) operations b Tax expense operations Net profit (lo operation aft Share of pro joint venture equity metho 13 Total profit (Other composite of the co		1	(0.16)		-		1.24
Deferred Tax Total Tax Ex Net Profit Lo continuing o Profit (loss) operations b Tax expense operations Net profit (lo operation aft Share of pro joint venture equity metho 13 Total profit (Other composite taxes Total Composite period attribut Comprehens attributable to Total compre period attribut noncontrolling 16 Details of ec Paid-up equ Face value of			\0.10/				
Total Tax Ex Net Profit Los continuing of Profit (loss) operations by Tax expense operations Net profit (loss) Net profit (loss) operations Net profit (loss) operation aft Share of proficit (loss) Share of proficit (loss) Total profit (loss) Tota							
Net Profit Los continuing of Profit (loss) poperations by Tax expense operations Net profit (lost) note of pro							
8 continuing o Profit (loss) 9 operations b Tax expense 10 operations Net profit (lo 11 operation aft Share of pro joint venture equity method 13 Total profit (Other composite taxes Total Composite taxes Total Composite to Total compre period attribut able to Total compre period attribut noncontrolling 16 Details of equivalent	ofit Loss for the period from	525.71			And the second		
Profit (loss) operations b Tax expense operations Net profit (lo 11 operation aft Share of pro joint venture equity metho 13 Total profit (Other composition taxes Total Composition Total comp		323.71	178.91	104.02	704.46	168.52	443.95
9 operations b Tax expense 10 operations Net profit (Id 11 operation aft Share of pro joint venture equity metho 13 Total profit (Id Other composition 14 taxes Total Composition Total composit			170.01	104.02	104.40	100.02	440.00
Tax expense operations Net profit (Id operation aft Share of pro joint venture equity metho Total profit (Id Other composition taxes Total Composition Total							
10 operations Net profit (Idoperation aft) Share of proficion to venture equity method 13 Total profit (Idoperation aft) Other composition 14 taxes Total Composition period attribution attributable to Total compreperiod attribution noncontrolling 16 Details of equipal according to the paid-up equipal according to the profit of the paid-up equipal according to the profit of the							
Net profit (Idoperation aft Share of projoint venture equity method Total profit (Idoperation attributable to Total compression attributable attribu	pense of discontinued						
11 operation aft Share of pro joint venture equity metho 13 Total profit (Other composition 14 taxes Total Composition period attribut Comprehens attributable to Total compre period attribut noncontrolling 16 Details of equ Paid-up equ Face value of	ons			·			
Share of projoint venture 12 equity method 13 Total profit (Other composition 14 taxes Total Composition 15 period attributable to Total compreserved attributable to Total compreserved attributable to Details of ed Paid-up equ Face value of	fit (loss) from discontinued						
joint venture equity method Total profit (Other composition taxes Total Composition period attributable to Total compreserved attributable to Total compreserved attributable period attributable to Total compreserved attributable to Tot	on after tax						
12 equity method 13 Total profit (Other composite taxes Total Composite period attributable to Total compression attributation attrib	of profit (loss) of associates and						
13 Total profit (Other composite) 14 taxes Total Composite (Definition of taxes Total Composite (Total profit (Total profi	ntures accounted for using						
Other composite taxes Total Composite period attributable to Total compreserved attributable to Total compreserved attributation noncontrolling Details of equal to Face value of taxes			170.04	404.60	757.75	100.70	112.05
14 taxes Total Comprehens attributable to Total compreperiod attribut noncontrolling Details of equal to the paid-up equal taxes	rofit (loss) for period	525.71	178.91	104.02	704.46	168.52	443.95
Total Compression 15 period attributable to Total compression attributable attributable to Total compression attributation attributation noncontrolling Details of ed Paid-up equivalent face value of the Paid-up equivalent face value equivalent face v	comprehensive income net of					e	
Total Compression 15 period attributable to Total compression attributable attributable to Total compression attributation attributation noncontrolling Details of ed Paid-up equivalent face value of the Paid-up equivalent face value equivalent face v							
15 period attribution Comprehens attributable to Total compreperiod attribution noncontrolling Details of equal to Paid-up equivalent to Total comprehension attribution noncontrolling Details of equal to Total	omprehensive income for the						
Comprehens attributable to Total compre period attribut noncontrolling Details of ed Paid-up equ Face value of							
attributable to Total compre period attribut noncontrolling Details of ed Paid-up equ Face value of	ehensive income for the period	23.18					
Total compression attribution noncontrolling 16 Details of ed Paid-up equ Face value of	ble to owners of parent		161.46	106.42	184.64	173.66	442.75
period attribut noncontrolling 16 Details of ed Paid-up equ Face value of	emprehensive income for the	502.38					
noncontrolling 16 Details of ed Paid-up equ Face value of	ttributable to owners of parent						
16 Details of ed Paid-up equ Face value of			17.44	(2.73)	519.82	(5.13)	1.20
Paid-up equ Face value o	of equity share capital			,		, , , , ,	
Face value of	equity share capital	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72
	alue of equity share capital(Rs.)	10.00	10.00	10.00	10.00	10.00	10.00
Details of the	of debt securities					310	2.2.2.2.2.2.
Paid-up debt					1	The state of the s	
	alue of debt securities	For	INDRAYANI	BIOTECH	IMITED /	15/	

K. Arryn Judelle Managing Director

18	Reserves excluding revaluation reserve						
19							
0.00	Earnings per share						
	Earnings per equity share for						
i	continuing operations	1.54	0.52	0.30	2.06	0.49	1.30
	Basic earnings (loss) per share from						
	continuing operations	1.54	0.52	0.30	2.06	0.49	1.30
	Diluted earnings (loss) per share from						
	continuing operations						
ii	Earnings per equity share for						
	Basic earnings (loss) per share from						
	discontinued operations						
	Diluted earnings (loss) per share from						
	discontinued operations	8					::
iii	Earnings per equity share						
	Basic earnings (loss) per share from	1.54					
	continuing and discontinued operations					91	
			0.52	0.30	2.06	0.49	1.30
	Diluted earnings (loss) per share from	1.54					
	continuing and discontinued operations				, and the desired of		
			0.52	0.30	2.06	0.49	1.30

Notes:

- 1. The above Consolidated financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors Directors at their meeting held on 14th Novembert 2022 and have been subjected to Limited review by the Statutory Auditors of the company. The above results have been prepared In accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- 2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).
- 3. Figures for three months ended 30 September 2022 as reported in these financials results are the balancing figures between audited figures, in respect of the full previous year and the published year to date figures upto the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial year had only been reviewed and not subject to audit.
- 4. There were no investor complaints pending at the beginning or at the end of the quarter. No compliants were received during the

5. Previous period figures have been regrouped wherever necessary.

Date: 14/11/2022 Place: Chennai

For INDRAYANI BIOTECH LIMITED

K. Lunn Lung Managing Director

M/s. INDRAYANI BIOTECH LIMITED BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032

CIN: L40100TN1992PLC129301

Unaudited Consolidated Statement of Assets & Liabilities

Particulars Particulars	Notes	30.09.2022	31.03.2022
ASSETS			7.791
A) Non - Current Assets			
a) Property Plant and Equipment	3	2,521.13	1,267.27
b) Capital Work in Progress	3	1,301.56	1,326.56
c) Goodwill	3	2,186.95	384.14
d) Other Intangible assets		2	
e) Financial Assets			
(i) Investments	4	0.05	0.05
(ii) Other Financial Assets		2 0	90.27
Non Current Tax Assets		34.04	112.75
Other Non Current assets	5	650.77	67.73
B) Current Assets			
a) Inventories	6	1,030.57	153.23
b) Financial Assets	"	1,000.07	155125
(i) Investments			
(ii) Trade Receivables	7	2,397.63	1,409.86
(iii) Cash and cash Equivalents	8	160.23	150.26
(iii) Other Financial Assets	9	282.30	49.67
c) Other Current assets	10	1,516.47	128.32
Total Assets	1 10	12,081.70	5,140.11
EQUITY & LIABILITIES	Т	12,001.70	5,140.11
A) Equity			
a) Equity Share Capital	11	4,347.72	3,422.72
b) Other Equity	12	1,038.79	-1,006.38
	12	-994.48	40.64
b) Non Controlling Interest within Equity		-994.40	40.04
B) LIABILITIES Non - Current Liabilities			
A- 10 (- 10 to			
a) Financial Liabilities	4.0	2 606 00	C70 F1
(i) Borrowings	13	2,696.98	678.51
(ii) Other financial Liabilities		25.44	FF 00
(ii) Financial Lease Liabilities	١ ا	35.44	55.00
b) Deffered Tax Liabilities	14	1.38	1.38
c) Other Non Current Liabilities			
Current Liabilities			
a) Financial Liabilities			
(i) Short Term Borrowings	15	2,172.32	1,110.27
(ii) Trade Payables			
(A) total outstanding dues of micro			
enterprises and small enterprises;			
(B) total outstanding dues of creditors other than micro enterprises and small	16	2,404.85	582.00
enterprises	10	2,707.03	362.00
(iii) Other financial Liabilities			
(ii) Financial Lease Liabilities		37.95	35.66
b) Other Current Liabilities	17	55.23	72.29
c) Provisions	18	285.52	148.02
Total Equity & Liabilities	10	12,081.70	5,140.11
Total Equity & Liabilities		12,001.70	J/170.11

For INDRAYANI BIOTECH LIMITED

M/s. INDRAYANI BIOTECH LIMITED BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032

CIN: L40100TN1992PLC129301

Unaudited Consolidated Statement of Cash Flow Amount in Rs. In Lakhs			
Particulars	As on 31-Sep-2022	As on 31-Mar-22	
Cash Flows From Operating Activities:-	31 3CP 2022	J2 FIG. 22	
Net Profit after Taxation	704.46	443.95	
Adjustment for Non cash items			
Add : Impairment of Fixed Assets	25.00		
Add : Depreciation	141.37	65.94	
Less: Interest Income Notional (As per Ind AS 109)	-2.88	-1.50	
Add : Notional Rent as per IND AS	1.53		
Less: Increase in Good will	-1,802.81		
Adjustment for Non Operating activities			
Add : Interest Paid	212.11	187.97	
Less : Interest income	1.25		
Cash Flow Before Working Capital changes:-	-719.97	696.36	
Decrease (Increase) in Inventories	-877.34	-44.31	
Decrease (Increase) in Trade receivables	-987.77	-933.25	
Decrease (Increase) in other current assets	-1,620.78	-72.36	
(Decrease) Increase in Short term borrowings	1,062.05	369.46	
(Decrease) Increase in Lease Liabilities	2.29	35.66	
(Decrease) Increase in Trade payables	1,822.85	247.72	
(Decrease) Increase in Other Current liabilities	-17.06	53.93	
(Decrease) Increase in Provisions	137.50	57.89	
Cash Flow Before Tax and Extraordinary Items:-			
Income Taxes Paid		æ	
Net Cash Flow From Operating Activities	-1,198.22	411.10	
Cash Flow from Investing Activities:-		_	
Less : Purchase of Capital Assets	-199.63	-118.91	
Less : Purchase of Investments	-733.48	-1.84	
Add : Rental Receipts			
Add : Amount of Interest Received			
Less : Sale of Capital Assets			
Decrease (Increase) in Loans and advances & Other assets	-414.06	64.94	
Net Cash flow used in Investing Activities	-1,347.17	-55.81	
Cash Flow from Financing Activities:-			
Increase in Borrowings	2,018.47		
Increase in Lease Liabilities	-19.56	55.00	
Interest Income Notional (As per Ind AS 109)	2.88	1.50	
Increase in Non Controlling Interest	-1,562.44	-4.61	
Increase in Share capital	925.00	1-1	
Share Premium collected	1,403.18	200	
Increase in Other Non current liabilities			
Interest expense	-212.11	-187.97	
Decrease in borrowings		-136.88	
Net Cash Flow From Financing Activities	2,555.42	-272.96	
Net Increase/(Decrease) in Cash and Cash Equivalents:-			
(Opening Balance)	150.20	67.87	
Net Cash Flow during the year	10.03	82.33	
(Closing Balance)	160.23	150.20	

For INDRAYANI BIOTECH LIMITED

K. Hanne June Managing Director

CA

VENKATESH & CO

Chartered Accountants

Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors,

Indrayani Biotech Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended September 2022. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for Venkatesh & Co

Chartered Accountants

FRN: 004636S

CA Dasaraty V

Partner

M No: 026336

UDIN: 22026336BDBCES2027 Chennai, 14th November 2022

CHENNAL

INDRAYANI BIOTECH LIMITED

Regd. Office:

BLOCK 1, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032

	600032							
	STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2022							
	Rs.							
		STANDALONE						
	DARTICIII ARS	Qu	arter Ended		Half Year E		Year Ended	
SR	PARTICULARS	30-09-2022	30-Jun-22	30-09-2021	30-09-2022	30-09-2021		
No		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income from Operations							
	(a) Net Sales/Revenue from Operations	1,592.16	1,559.80	1,430.99	3,151.96	2,855.40	5,798.85	
	(b) Other Income	6.18	38.24	3.70	44.42	6.23	22.08	
	Total Income from Operations	1,598.34	1,598.04	1,434.69	3,196.38	2,861.63	5,820.94	
2								
	(a) Cost of Materials consumed	765.95	966.33	954.64	1,732.28	1,895.24	3,971.31	
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	850						
	(c) Employee benefits expenses	391.29	344.35	254.79	735.64	534.02	897.29	
\neg	(d) Finance Costs	56.73	39.03	52.90	95.76	85.14	187.97	
	(e) Depreciation and amortisation expense	15.82	11.67	8.46	27.49	16.87	34.43	
	(f) Other expenses	214.02	112.43	53.80	326.45	140.91	307.38	
_	Total Expenses	1,443.81	1,473.81	1,324.59	2,917.62	2,672.18	5,398.38	
	Total profit / (Loss) before exceptional	1,440.01	1,470.01	1,021.00		2,0.2	0,000.00	
3	items and tax	154.53	124.23	110.10	278.76	189.45	422.56	
4		10 1100						
-	Add:Share of Profit In Associates							
	Less: Written of CWIP	(25.00)			(25.00)			
5	Total profit / (Loss) before tax	129.53	124.23	110.10	253.76	189.45	422.56	
	Total profit / (Loss) before tax	Secure Constant						
7	Tax Expenses							
	Current Tax							
	Deferred Tax					//		
	Total Tax Expenses							
	Net Profit Loss for the period from			***************************************	244 147 147 147 147	A -02 128000	Luttotte: Luto	
8	continuing operations	129.53	124.23	110.10	253.76	189.45	422.56	
	Profit (loss) from discontinued operations							
9	before tax		1					
10	Tax expense of discontinued operations							
	Net profit (loss) from discontinued							
11	operation after tax							
	Share of profit (loss) of associates and							
	joint ventures accounted for using equity							
12	method	400.50	404.00	440.40	050.70	400.45	400.50	
	Total profit (loss) for period	129.53	124.23	110.10	253.76	189.45	422.56	
14	Other comprehensive income net of taxes						·	
4.5	Total Comprehensive income for the period	129.53	124.23	110.10	253.76	189.45	422.56	
15	attributable to	129.03	124.23	110.10	253.16	105.45	422.50	
	Comprehensive income for the period	129.53	124.23	110.10	253.76	189.45	422.56	
-	attributable to owners of parent Total comprehensive income for the period	128.00	124.23	110.10	200.70	100.40	722.00	
	attributable to owners of parent noncontrolling							
	•							
	Potable of aguity share capital							
10	Details of equity share capital	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72	
ı	Paid-up equity share capital	10.00	10.00		10.00	10.00		
	Face value of equity share capital(Rs.)	10.00	10.00	10.00	10.00	10.00	10.00	



For INDRAYANI BIOTECH LIMITED

Managing Director

17	Details of debt securities						
	Paid-up debt capital						
	Face value of debt securities						
18	Reserves excluding revaluation reserve						
19							
20	Earnings per share						
	Earnings per equity share for continuing	0.38	0.36	0.32	0.74	0.55	1.23
1.	operations	0.36	0.36	0.32	0.74	0.55	1.25
	Basic earnings (loss) per share from continuing operations	0.38	0.36	0.32	0.74	0.55	1.23
	Diluted earnings (loss) per share from						
	continuing operations						
	Earnings per equity share for discontinued						
ii	operations						
	Basic earnings (loss) per share from						
	discontinued operations						
	Diluted earnings (loss) per share from						
	discontinued operations						
III	Earnings per equity share						
	Basic earnings (loss) per share from						
	continuing and discontinued operations	0.38	0.36	0.32	0.74	0.55	1.23
	Diluted earnings (loss) per share from						
	continuing and discontinued operations	0.38	0.36	0.32	0.74	0.55	1.23

Notes:

- 1. The above financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors
 Directors at their meeting held on 14th November 2022 and have been subjected to Limited review by the Statutory Auditors of the
 company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under
 Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies
 (Indian Accounting Standards) Amendment Rules, 2016.
- 2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).
- 3. Figures for three months ended 30 September 2022 as reported in these financials results are the balancing figures between audited figures, in respect of the full previous year and the published year to date figures upto the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial year had only been reviewed and not subject to audit.
- 4. There were no investor complaints pending at the beginning or at the end of the quarter. No compliants were received during the quarter.
- 5. Previous period figures have been regrouped wherever necessary.

Date: 14/11/2022 Place: Chennai

For INDRAYANI BIOTECH LIMITED

Maring Director

M/s. INDRAYANI BIOTECH LIMITED

CIN: L40100TN1992PLC129301

BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032

Unaudited Standalone Statement of Assets and Liabilities	Y. T.		RESERVE AND A
Particulars Particulars	Notes	As at 30.09.2022	As at 31.03.2022
ASSETS			
A) Non - Current Assets			
a) Property Plant and Equipment	3	1,221.58	1,149.39
c) Capital Work in Progress	3	1,296.96	1,321.96
d) Goodwill	3	383.53	383.53
e) Other Intangible assets			
f) Financial Assets			
(i) Investments	4	752.01	18.53
(ii) Other Financial Assets			=
Non Currrent Tax Assets		90.27	90.27
Other Non Currrent Tax Assets		112.75	112.75
f) Other Non Current assets	5	522.16	67.73
B) Current Assets			
a) Inventories	6	230.97	136.55
b) Financial Assets		_	
(i) Investments			
(ii) Trade Receivables	7	2,154.67	1,287.64
(iii) Cash and cash Equivalents	8	115.17	144.52
(iii) Other Financial Assets	9	142.16	49.67
c) Other Current assets	10	1,205.63	180.92
Total Assets		8,227.85	4,943.45
EQUITY & LIABILITIES			
A) Equity			-
a) Equity Share Capital	11	4,347.72	3,422.72
b) Other Equity	12	651.79	-1,005.14
B) LIABILITIES			
Non - Current Liabilities			
a) Financial Liabilities			
(i) Borrowings	13	564.73	678.51
(ii) Other financial Liabilities			a a
b) Deffered Tax Liabilities	14	1.38	1.38
c) Other Non Current Liabilities			
Current Liabilities			
a) Financial Liabilities			
(i) Short Term Borrowings	15	1,862.09	994.84
(ii) Trade Payables			
(A) total outstanding dues of micro enterprises and small enterprises;			
(B) total outstanding dues of creditors other than micro enterprises and small enterprises	16	620.27	644.93
(iii) Other financial Liabilities			
b) Other Current Liabilities	17	41.84	74.28
c) Provisions	18	138.02	131.94
Total Equity & Liabilities		8,227.85	4,943.44

For INDRAYANI BIOTECH LIMITED

Managing Director



M/s. INDRAYANI BIOTECH LIMITED BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032

CIN: L40100TN1992PLC129301

Unaudited Standalone Statement of Cash Flow	THE PERSON NAMED IN	Amount in Rs.
Particulars	As on	As on
Cash Flows From Operating Activities:-	30-Sep-22	31-Mar-22
Net Profit after Taxation	253.76	422.56
Adjustment for Non cash items	255.70	122.50
Add : Impairment of Fixed Assets	25.00	
Add : Depreciation	27.49	34.43
with Contractive Tracks Tracks (All States)	-2.88	-1.50
Less : Interest Income Notional (As per Ind AS 109) Add : Notional Rent as per IND AS	1.53	1.50
Adjustment for Non Operating activities	1.55	
Add: Interest Paid	95.76	187.97
S \$600 0 10 D	-1,25	107.57
Less : Interest income	399.41	643.46
Cash Flow Before Working Capital changes:- Decrease (Increase) in Inventories	-94.42	-28.17
	-867.04	-810.83
Decrease (Increase) in Trade receivables	-1,118.73	-130.80
Decrease (Increase) in other current assets	867.26	266.98
(Decrease) Increase in Short term borrowings	-24.66	302.82
(Decrease) Increase in Trade payables	-32.43	56.15
(Decrease) Increase in Other Current liabilities	6.08	46.99
(Decrease) Increase in Provisions	6.06	40.55
Cash Flow Before Tax and Extraordinary Items:		
Income Taxes Paid	-864.53	346.60
Net Cash Flow From Operating Activities	-804.53	340.00
Cash Flow from Investing Activities:-	-99.68	-6.31
Less : Purchase of Capital Assets	-733.48	-0.51
Less : Purchase of Investments	-/33.46	
Add : Rental Receipts		
Add : Amount of Interest Received		
Less : Sale of Capital Assets	-454.43	64.94
Decrease (Increase) in Loans and advances & Other assets		58.63
Net Cash flow used in Investing Activities	-1,287.59	36.03
Cash Flow from Financing Activities:-		
Increase in Borrowings	2.00	1.50
Interest Income Notional (As per Ind AS 109)	2.88	1.50
Increase in Share capital	925.00	
Share Premium collected	1,403.18	
Increase in Other Non current liabilities	05.76	197.07
Interest expense	-95.76	-187.97
Decrease in borrowings	-112.53	-136.88 - 323.35
Net Cash Flow From Financing Activities Net Increase/(Decrease) in Cash and Cash Equivalents:-	2,122.77	-323.35
(Opening Balance)	144.53	62.65
Net Cash Flow during the year	-29.35	81.88
(Closing Balance)	115.18	144.53

For INDRAYANI BIOTECH LIMITED

Managing Director

